Why AtriCure, Inc. Shares Surged
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of AtriCure , a developer of cardiac surgical ablation systems, vaulted higher by as much as 21% after announcing preliminary results for the fourth quarter of 2013 and issuing its 2014 full-year guidance.
So what: For the fourth quarter, AtriCure expects to report $21.9 million in revenue, a 19% increase over the previous year with domestic revenue growing by 20% and international revenue increasing 17%. For 2014, management is projecting full-year revenue of $100 million to $103 million, representing a 22%-26% increase over 2013 with organic growth of 13%-15%. ArtiCure also anticipates its recently closed Estech transaction will be dilutive to EPS in 2014 and accretive to EPS in 2015 and beyond. By comparison, Wall Street had expected just $20.1 million in revenue during the fourth quarter and $90.1 million in sales in 2014.
Now what: What we have here is a mixed bag. On the one hand, ArtiCure's organic growth and growth by acquisitions could fuel sales growth of 10% for at least the next couple of years. In addition, an aging baby boomer population is widely anticipated to a boon to the health-care industry and medical device companies like ArtiCure. On the other hand, ArtiCure's share price has already soared threefold over the past year and it still doesn't have any profits to show for it. While its top line is headed in the right direction, I have a hard time suggesting anyone chase this higher without any tangible profits. Until I see a very meaningful reduction in losses, I would suggest watching this company from the sidelines.
This is the real opportunity you may not want to pass up!
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.
The article Why AtriCure, Inc. Shares Surged originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.